GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: Example 6 [WO2014169843]
luvometinib is an approved drug
Compound class:
Synthetic organic
Comment: The chemical structure for luvometinib was obtained from WHO proposed INN list 131 (August 2024). The INN document records luvometinib as a mitogen-activated protein kinase (MEK) inhibitor and antineoplastic agent. It is one of the compounds claimed in patent WO2014169843A1 (Fochon Pharmaceutical) [4]. Fochon Pharmaceutical have one MEK inhibitor in their declared development pipeline, FCN-159. Published information about FCN-159 indicates that it is an orally available MEK1/2 inhibitor lead for the treament of BRAF- or RAS-driven tumours [2-3]. Inhibition of MEK1/2 disrupts downstream MAPK signalling that is activated by upstream mutant RAF/RAS enzymes in malignancies.
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
| Approved drug? | Yes. China NMPA (2025) |
IUPAC Name ![]() |
| N-[3-[6-cyclopropyl-3-fluoro-4-(2-fluoro-4-iodoanilino)-1-methyl-2,5-dioxopyrido[2,3-d]pyridazin-8-yl]phenyl]cyclopropanesulfonamide |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 13248 | luvometinib |
Synonyms ![]() |
| Example 6 [WO2014169843] |
Database Links ![]() |
|
| CAS Registry No. | 2739690-43-6 (source: WHO INN record) |
| GtoPdb PubChem SID | 500839905 |
| PubChem CID | 135210935 |
| Search Google for chemical match using the InChIKey | RJFDJJABNSVLRB-UHFFFAOYSA-N |
| Search Google for chemicals with the same backbone | RJFDJJABNSVLRB |
| Search PubMed clinical trials | luvometinib |
| Search PubMed titles | luvometinib |
| Search PubMed titles/abstracts | luvometinib |
| UniChem Compound Search for chemical match using the InChIKey | RJFDJJABNSVLRB-UHFFFAOYSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | RJFDJJABNSVLRB-UHFFFAOYSA-N |